KNSA

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

Retrieved on: 
Tuesday, April 2, 2024
Janus, Week, CD154, Rheumatoid arthritis, Jaki, Patient, Cohort, KNSA, Joint, Clinical trial, C-reactive protein, CD40, Least squares, Pharmacokinetics, Safety, FDA, Rheumatoid factor, Pharmaceutical industry

HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced plans to initiate a Phase 2b trial with abiprubart in Sjogren’s Disease. Additionally, the company announced data from Cohort 4 of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis. Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction.

Key Points: 
  • HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced plans to initiate a Phase 2b trial with abiprubart in Sjogren’s Disease.
  • Additionally, the company announced data from Cohort 4 of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis.
  • Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction.
  • “We believe abiprubart has the potential to provide meaningful benefit to patients suffering from Sjogren’s Disease, a debilitating disorder with no current FDA-approved therapies.

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

Retrieved on: 
Wednesday, February 28, 2024
Real-World Evidence, Cohort, KNSA, C-reactive protein, Rheumatoid factor, Recurrence, Investment, Telephone, Partnership, Growth, ID, Joint, Genentech, Roche, Rheumatoid arthritis, American College, Webcast, Patient, Pericarditis, Paradigm, Prescription, CD40, Pharmaceutical industry

HAMILTON, Bermuda, Feb. 28, 2024 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported fourth quarter and full-year 2023 financial results and recent portfolio execution.

Key Points: 
  • Total revenue for the fourth quarter of 2023 was $83.4 million, compared to $61.9 million for the fourth quarter of 2022.
  • Total operating expenses for the fourth quarter of 2023 were $83.3 million, compared to $55.8 million for the fourth quarter of 2022.
  • Net income for the fourth quarter of 2023 was $25.2 million, compared to net income of $4.5 million for the fourth quarter of 2022.
  • Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 28, 2024, to discuss fourth quarter and full-year 2023 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Retrieved on: 
Wednesday, February 21, 2024
KNSA, ID, Telephone

HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2023 financial results and recent portfolio execution.

Key Points: 
  • HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2023 financial results and recent portfolio execution.
  • A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com .
  • Individuals interested in participating in the call via telephone may register here .
  • A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

Kiniksa Pharmaceuticals Provides Corporate Update

Retrieved on: 
Thursday, January 4, 2024
Mean difference, Conference, Partnership, Prescription, Rheumatoid arthritis, CD40, Cohort, Week, Least squares, KNSA, C-reactive protein, Joint, Rheumatoid factor, Investment, Webcast, Patient, Pharmaceutical industry

HAMILTON, Bermuda, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today provided a corporate update.

Key Points: 
  • HAMILTON, Bermuda, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today provided a corporate update.
  • In fact, at the end of 2023 Kiniksa penetrated approximately 9% into the multiple-recurrence population, compared to approximately 5% at the end of 2022,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa.
  • Kiniksa has now completed enrollment in a fourth cohort (Cohort 4) of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis.
  • Kiniksa is now evaluating potential partnership opportunities to advance development of mavrilimumab, which has generated positive data in mid-stage clinical trials across multiple indications.

Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 2, 2024
Webcast, Conference, KNSA

HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Key Points: 
  • HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
  • A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com .
  • A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution

Retrieved on: 
Tuesday, October 31, 2023
KNSA, Cohort, Telephone, Pericarditis, Rheumatoid arthritis, Prescription, ID, Clinical trial, Webcast, GM-CSF, Investment, Patient, Beauty salon, Pharmaceutical industry, Video game

HAMILTON, Bermuda, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported third quarter 2023 financial results and recent portfolio execution.

Key Points: 
  • – ARCALYST® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth –
    HAMILTON, Bermuda, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported third quarter 2023 financial results and recent portfolio execution.
  • We now expect data from Cohorts 1-3 in the first quarter of 2024.”
    ARCALYST net product revenue was $64.8 million for the third quarter of 2023.
  • Total operating expenses for the third quarter of 2023 were $78.0 million, compared to $52.7 million for the third quarter of 2022.
  • Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, October 31, 2023, to discuss third quarter 2023 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023

Retrieved on: 
Tuesday, October 24, 2023
KNSA, Telephone, ID, Rare-earth element, Internet service provider, Broadcasting

HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8:30 a.m. Eastern Time to report its third quarter 2023 financial results and recent portfolio execution.

Key Points: 
  • HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8:30 a.m. Eastern Time to report its third quarter 2023 financial results and recent portfolio execution.
  • A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com .
  • Individuals interested in participating in the call via telephone may register here .
  • A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution

Retrieved on: 
Tuesday, July 25, 2023
Patient satisfaction, Telephone, Prescription, Genentech, ID, Patient, Investment, GM-CSF, Webcast, Growth, KNSA, FDA, Rheumatoid arthritis, Roche, Pericarditis, Fine chemical, Pharmaceutical industry, Video game, Life insurance

HAMILTON, Bermuda, July 25, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported second quarter 2023 financial results and recent portfolio execution.

Key Points: 
  • – ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the midpoint –
    HAMILTON, Bermuda, July 25, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported second quarter 2023 financial results and recent portfolio execution.
  • Total revenue for the second quarter of 2023 was $71.5 million, compared to $27.0 million for the second quarter of 2022.
  • Total operating expenses for the second quarter of 2023 were $74.6 million, compared to $46.3 million for the second quarter of 2022.
  • Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, July 25, 2023, to discuss second quarter 2023 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023

Retrieved on: 
Monday, July 17, 2023
Telephone, KNSA, ID, Rare-earth element, Internet service provider

HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution.

Key Points: 
  • HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution.
  • A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com .
  • Individuals interested in participating in the call via telephone may register here .
  • A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, June 6, 2023
Goldman Sachs, KNSA, Goldman, Conference, News, Video game, Financial adviser

HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time).

Key Points: 
  • HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time).
  • A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com .
  • A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.